X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs STERLING BIOTECH - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA STERLING BIOTECH SUN PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 36.7 -0.4 - View Chart
P/BV x 4.1 0.0 26,521.9% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUN PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
STERLING BIOTECH
Dec-13
SUN PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs84211 8,020.0%   
Low Rs5723 16,835.3%   
Sales per share (Unadj.) Rs131.626.8 491.0%  
Earnings per share (Unadj.) Rs32.7-15.0 -218.6%  
Cash flow per share (Unadj.) Rs38.0-5.5 -695.1%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs152.754.9 278.3%  
Shares outstanding (eoy) m2,399.26267.87 895.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.40.3 2,072.6%   
Avg P/E ratio x21.6-0.5 -4,654.2%  
P/CF ratio (eoy) x18.6-1.3 -1,463.9%  
Price / Book Value ratio x4.60.1 3,657.2%  
Dividend payout %10.70-   
Avg Mkt Cap Rs m1,696,8771,862 91,146.7%   
No. of employees `00017.51.4 1,293.6%   
Total wages/salary Rs m49,023547 8,965.4%   
Avg. sales/employee Rs Th18,028.35,303.3 339.9%   
Avg. wages/employee Rs Th2,798.8403.8 693.0%   
Avg. net profit/employee Rs Th4,479.5-2,959.0 -151.4%   
INCOME DATA
Net Sales Rs m315,7847,181 4,397.7%  
Other income Rs m6,23243 14,627.9%   
Total revenues Rs m322,0167,223 4,458.0%   
Gross profit Rs m100,893947 10,655.1%  
Depreciation Rs m12,6482,543 497.3%   
Interest Rs m3,9984,377 91.3%   
Profit before tax Rs m90,479-5,931 -1,525.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,116-1,924 -629.6%   
Profit after tax Rs m78,462-4,007 -1,958.4%  
Gross profit margin %31.913.2 242.3%  
Effective tax rate %13.432.4 41.3%   
Net profit margin %24.8-55.8 -44.5%  
BALANCE SHEET DATA
Current assets Rs m329,53714,335 2,298.8%   
Current liabilities Rs m178,87049,809 359.1%   
Net working cap to sales %47.7-494.0 -9.7%  
Current ratio x1.80.3 640.1%  
Inventory Days Days79403 19.6%  
Debtors Days Days83171 48.8%  
Net fixed assets Rs m204,76655,432 369.4%   
Share capital Rs m2,399268 895.6%   
"Free" reserves Rs m363,99713,935 2,612.1%   
Net worth Rs m366,39714,701 2,492.3%   
Long term debt Rs m14,3619,478 151.5%   
Total assets Rs m614,10273,988 830.0%  
Interest coverage x23.6-0.4 -6,657.3%   
Debt to equity ratio x00.6 6.1%  
Sales to assets ratio x0.50.1 529.8%   
Return on assets %13.40.5 2,680.8%  
Return on equity %21.4-27.3 -78.6%  
Return on capital %24.8-6.4 -386.5%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m44,1181,860 2,372.2%   
Fx outflow Rs m24,48425 98,369.2%   
Net fx Rs m19,6341,835 1,070.0%   
CASH FLOW
From Operations Rs m70,8221,719 4,120.7%  
From Investments Rs m-42,216-3,148 1,341.0%  
From Financial Activity Rs m-22,8541,426 -1,602.7%  
Net Cashflow Rs m6,107-3 -179,608.8%  

Share Holding

Indian Promoters % 63.7 33.9 187.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.0 -  
FIIs % 23.0 9.9 232.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 8.3 39.3 21.1%  
Shareholders   133,026 21,482 619.2%  
Pledged promoter(s) holding % 0.5 55.9 0.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Nifty Crosses 11,500-Mark; L&T Surges 4% on Buyback News(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.2% while the Hang Seng is up 0.7%.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 20, 2018 10:41 AM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS